SPIA
MYGN icon

Steward Partners Investment Advisory’s Myriad Genetics MYGN Stock Holding History

Steward Partners Investment Advisory’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58
Closed -$308 – 4342
2025
Q2 		$308 Hold
58
– – ﹤0.01% 4004
2025
Q1 		$514 Hold
58
– – ﹤0.01% 3860
2024
Q4 		$795 Sell
58
-35
-38% -$646 ﹤0.01% 3795
2024
Q3 		$2.55K Buy
93
+58
+166% +$1.57K ﹤0.01% 3393
2024
Q2 		$856 Sell
35
-94
-73% -$2.06K ﹤0.01% 3411
2024
Q1 		$2.75K Hold
129
– – ﹤0.01% 3227
2023
Q4 		$2.47K Buy
+129
New +$2.23K ﹤0.01% 3167

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Steward Partners Investment Advisory's MYGN Position: Q3 2025 in Review

Steward Partners Investment Advisory sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 58 shares — an estimated $308 sold.

Steward Partners Investment Advisory first reported a position in MYGN in Q4 2023 and held it in 7 quarters. The position peaked at $2.75K in Q1 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Steward Partners Investment Advisory reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 58 Myriad Genetics shares in Q3 2025, an estimated $308.
  • Steward Partners Investment Advisory first reported a position in Myriad Genetics in Q4 2023 and held it in 7 quarters.
  • Steward Partners Investment Advisory's Myriad Genetics position peaked at $2.75K in Q1 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2025, filed 12 Nov 2025.